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Abstract 
Repurposing has gained momentum globally and become an alternative avenue for drug discovery because of its better success rate, 
and reduced cost, time and issues related to safety than the conventional drug discovery process. Several drugs have already been 
successfully repurposed for other clinical conditions including drug resistant tuberculosis (DR-TB). Though TB can be cured 
completely with the use of currently available anti-tubercular drugs, emergence of drug resistant strains of Mycobacterium tuberculosis 
and the huge death toll globally, together necessitate urgently newer and effective drugs for TB. Therefore, we performed virtual 
screening of 1554 FDA approved drugs against murE, which is essential for peptidoglycan biosynthesis of M. tuberculosis. We used 
Glide and AutoDock Vina for virtual screening and applied rigid docking algorithm followed by induced fit docking algorithm in 
order to enhance the quality of the docking prediction and to prioritize drugs for repurposing. We found 17 drugs binding strongly 
with murE and three of them, namely, lymecycline, acarbose and desmopressin were consistently present within top 10 ranks by both 
Glide and AutoDock Vina in the induced fit docking algorithm, which strongly indicates that these three drugs are potential 
candidates for further studies towards repurposing for TB. 
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Background: 
New drugs for the effective treatment of tuberculosis are greatly 
needed now than ever due to the increasing trend in the 
emergence of drug resistant strains of Mycobacterium tuberculosis 
(M. tuberculosis), especially in India, China and Russian 
Federation [1]. Poor success rate of the treatment of drug resistant 
tuberculosis (DR-TB) than drug sensitive TB alarmingly indicates 
for newer and effective drugs urgently for the successful 
treatment and control of TB, globally [1]. It has been reported that 
the current drug discovery pipeline for TB appears to be healthy 
since a good number of candidate drugs are being evaluated in 
different phases of clinical and preclinical research [2, 3]. 
However, emergence of resistant mycobacteria even for newer 
drugs also cannot be ruled out in the future, thus, search for 
newer and alternative drugs for the treatment of TB should be a 
continuous process to ensure the sustained control of TB.  
 
The conventional drug discovery process is challenged by several 
obstacles including expensive budget, lengthy process for 
discovery of new compounds, and most importantly meagre 
success rate [4]. Identifying new applications for already FDA-
approved drugs for clinical conditions other than intended use is 
becoming a promising new avenue to pursue for drug discovery, 
a process defined as repurposing or repositioning [4]. Strategy of 
repurposing of already approved drugs appears to be a viable 
approach since it reduces the time spent in establishing 
pharmacokinetics and safety issues for human use [4]. This 
approach has been already adopted as a successful strategy in 
various clinical conditions including, premenstrual dysphoria 
(fluoxetine,  primarily used for depression), multiple myeloma 
(thalidomide, primarily used for sedation, nausea and insomnia) 
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[4]; the process of repurposing has recently been recognised and 
well supported by international agencies including National 
Institute of Health, USA and Medical Research Council, UK for 
research funding to explore possible repurposing of drugs for 
various diseases and to understand their mechanisms [5]. 
Fluoroquinolones, clofazimine, linezolid are few drugs that are 
successfully repurposed in the treatment of drug resistant 
tuberculosis [6].  
 
The genome of M. tuberculosis encodes for about 4000 proteins [7]. 
Therefore, selection of a protein as a drug target is crucial for 
drug discovery for TB. Extensive research, including 
bioinformatics based studies has been carried out to identify and 
prioritize drug targets for TB [8, 9]. Essentiality of protein for the 
pathogen and absence of homolog in eukaryotes are commonly 
used criteria for drug target selection, which we have used in the 
present study. The gene murE (Rv2158c) is an essential gene for 
the Mycobacterium tuberculosis since it encodes for a protein, UDP-
N-acetylmuramoyl-L-alanyl-D-glutamate--2,6-diaminopimelate 
ligase that catalyzes a  biochemical reaction essential for the 
biosynthesis of peptidoglycan of M. tuberculosis and it does not 
have a homolog in eukaryotes [10]. Therefore, murE has been 
suggested as a promising target for new drug discovery for 
tuberculosis and thus, its crystal structure has been determined in 
the presence of the substrate, UDP-MurNAc-l-Ala-d-Glu (UAG) 
[11]. Based on these evidences, we selected murE of M. 
tuberculosis as the drug target in the present study and performed 
virtual screening for 1554 FDA approved drugs using Glide and 
AutoDock Vina. We employed rigid docking algorithm and 
subsequently induced fit docking algorithm in order to enhance 
the quality of the docking prediction and to prioritize drugs for 
repurposing for TB.  
 
Table 1: Prioritized drugs which show strong binding interactions with murE of M. tuberculosis 
DrugBank 
ID 
Drug  
name 
Primary use* Glide  
score 
Glide  
Rank 
AutoDock 
Vina 
Binding 
Affinity 
ADV  
Rank 
RMSD   
(Ao) 
Amino acids of murE 
interacting with drugs  
DB08995 Diosmin Venous disease -14.605109 1 -14.9 32 0.923 S84, T85, Q70, H91, R128,  T201 
DB01249 Iodixanol 
Contrast agent 
during 
coronary 
angiography. 
-
12.669883 2 -17.5 20 0.924 S84, R230, E198, L67,  R128,   A193, T201, R68, K396, D250 
DB00256 Lymecycline Various bacterial infections 
-
12.614792 3 -24.3 1 0.922 S84, E198, R230, T86, R128,   H248, D250 
DB00284 Acarbose Type 2 diabetes. -12.064307 4 -24.1 2 0.91 
S84,  S222, R230, T195, T85, T86, Q70, L67, A79, R128, 
H224  
DB08874 Fidaxomicin 
Clostridium 
difficile- 
associated 
diarrhea. 
-
11.250336 5 -19.8 12 0.985 R424, T82 
DB00224 Indinavir HIV/AIDS -11.217933 6 -15.3 30 0.918 S84, T195, R230, T85, T86, R128 
DB00035 Desmopressin Diabetes insipidus -11.019141 7 -23.3 3 0.927 
S84, R230, T195, T86, T85,  L67, A69, Q70, R128, H248, 
K157 
DB06663 Pasireotide Cushing’s disease. -10.852191 8 -18.6 17 0.975 
T86, Q70 
 
DB06810 Plicamycin Antineoplastic antibiotic. 
-
10.471306 9 -19 15 0.926 
S84, R230,  S222, T195, T85, T86, Q70, L67, A79, K157, 
R128, H224 
DB02638 Terlipressin Hypotension. -10.34453 10 -11.1 53 0.981 R230, S222, T195, T82, R424 
DB00520 Caspofungin Antifungal drug -10.004357 12 -20.4 9 0.907  A69, K157 
DB00512 Vancomycin Staphylococci infections. -9.474767 19 -23.2 4 0.907 T85, T86, Q70, L67 
DB00407 Ardeparin 
Postoperative 
venous thrombosis. 
 
-7.873831 29 -20.4 10 0.911  S84, R230, S222, T195 T85, T86, Q70, L67,  R128, H224 
DB01141 Micafungin Antifungal drug -5.873 47 -23.1 5 0.901 T86 
DB00290 Bleomycin 
Antineoplastic,  
especially for solid 
tumors. 
-3.831 48 -20.7 8 0.92 G70 
DB00403 Ceruletide Paralytic ileus. -3.7831 50 -21.7 6 0.9 T82 
DB00781 Polymyxin B  Sulfate 
Infections of the  
urinary tract, 
meninges,  
and blood stream. 
-1.81 52 -20.8 7 0.97 T85 
Amino acids in boldface are from the active site of the murE as provided in the crustal structure [11, 12]. *The primary use of all of the drugs provided in this table were 
referred from DrugBank [14]. RMSD: Root-mean-square deviation. ADV: AutoDock Vina  
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Methodology: 
Preparation of drug target and drug-library 
Atomic coordinates of murE was downloaded from Protein Data 
Bank (PDB ID: 2WTZ) [12] which has been used in previous 
study for docking based drug discovery [13]. Protein preparation 
wizard (Schrödinger, USA, 2014) was employed to prepare the 
target protein file for virtual screening. The structure was 
prepared for docking by following the standard procedure which 
includes, addition of hydrogen, assigning bond orders, removal 
of water molecules, optimization of hydrogen bonds, and energy 
minimization. The drug library consists of 1554 FDA approved 
drugs which were obtained from DrugBank [14]. LigPrep 
(Schrödinger, USA, 2014) was used to prepare the drug-library 
since it helps to prepare high quality, single, low-energy, 3D 
structure with correct chiralities, and apply force field for energy 
minimization for each entry of the chemical structure provided in 
the drug-library.  
 
Virtual screening 
All the 1554 drugs retrieved from DrugBank were screened 
against murE independently by using two docking methods 
namely Glide (Schrödinger) and AutoDock Vina (ADV) through 
PyRx (0.8) [15, 16]. In the initial round of screening, rigid docking 
was employed; for the selected drugs which were present in top 
10% in the rigid docking by both Glide and ADV, induced fit 
docking was performed for further prioritization. Using Glide, 
extra precision (Glide XP) method was used to generate grid 
around the active side residues with default settings and Glide 
score was used to rank the drugs after docking. AutoDock Vina 
was used as the second method through PyRx software in order 
to obtain consistent results, and binding energy of the docked 
complex was used to rank and shortlist drugs. The procedure 
applied in the present study has been illustrated in Figure 1. 
Molecular interactions were also analysed for all of the 
shortlisted drugs with murE.  RMSD value of the docked complex 
and original crystal structure of the target were also calculated. 
Binding affinity, molecular interactions and RMSD value were 
collectively used to prioritize drugs as potential candidates for 
repurposing for tuberculosis. 
 
Results and Discussion: 
Virtual screening of 1554 FDA approved drugs against murE of 
M. tuberculosis was performed using two different molecular 
docking tools and by employing rigid docking followed by 
induced fit docking algorithms. At the end of first round of 
docking (rigid docking) 53 drugs were ranked within top 10% by 
both Glide and AutoDock Vina. Further, induced fit docking of 
the 53 shortlisted drugs with murE enabled us to prioritize 17 
drugs as they were found within top 10 ranks either by Glide or 
ADV (Figure 1). A total of 3 drugs, namely lymecycline (rank 3 
by Glide and rank 1 by ADV), acarbose (4 and 2) and 
desmopressin (7 and 3) were ranked consistently within top 10 
ranks by both Glide and ADV. RMSD value for each of the 
docked complex relative to the crystal structure of the murE was 
calculated and it was observed that all of the 17 shortlisted drugs 
had value lesser than 1Ao. More details about these 17 prioritized 
drugs, including binding affinity with murE, RMSD value, and 
molecular interactions with the target protein, and the primary 
use of each of the drugs are provided in the Table 1.  
 
 
Figure 1: The protocol employed in the prioritization of drugs against murE of M. tuberculosis.  
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Based on the crystal structure of the murE, amino acids, T195, 
S222, R230, E198, L67, S84, Q70, A69, T86, T85 were reported to 
involve in the molecular interactions with UAG [11, 12]. 
Molecular interactions between shortlisted drugs and murE were 
analysed and the interacting amino acid residues are provided in 
the Table 1 and those residues known to be present in active site 
of the murE are provided in boldface [11, 12]. Lymecycline was 
found to be the top most drug by ADV ranking and rank 3 by 
Glide scoring. When the molecular interactions were analysed, it 
was found that lymecycline interact with seven amino acids of 
murE (Table 1) including,  S84, T86, E198 and R230 which are 
reported to be present in the active site of the murE [11, 12].  The 
RMSD value of the lymecycline and murE docked complex 
relative to the crystal structure of the murE was found to be 
0.922Ao. Acarbose was another drug ranked consistently within 
top 10 ranks by both ADV (2) and Glide (4) and the RMSD value 
was calculated to be 0.91Ao. Acarbose was found to interact with 
11 amino acids of murE (Table 1); among them, eight residues 
(S84, S222, R230, T195, T85, T86, Q70 and L67) are present in the 
active site of the murE [11, 12]. Similarly, desmopressin was 
ranked 3 by ADV and 7 by Glide and the RMSD values were 
0.927Ao. Desmopressin was also found to interact with 11 amino 
acids including eight amino acids from the active site of the murE 
(S84, R230, T195, T86, T85, L67, A69 and Q70) [11,12]. In an earlier 
study of murE of M. tubeculosis carried out by Singh et al (2014), 
most of the amino acids from the active site were demonstrated 
to interact with docked molecules, thus, such molecules were 
suggested as potential inhibitors of the enzyme [17]. Consistent 
ranking by both Glide and AutoDock Vina and by rigid docking 
as well as induced fit docking, strong molecular interactions with 
that of amino acids in the active site of the murE and significant 
RMSD values collectively suggest that these three drugs, 
lymecycline, acarbose and desmopressin are high-confident 
drugs for repurposing for TB. Molecular interactions between 
murE and the three drugs, lymecycline, acarbose and 
desmopressin have been illustrated in the Figure 2.  Among these 
three drugs, lymecycline is primarily used for the treatment of 
various other bacterial infections [14], which led us to form a 
hypothesis that 'lymecycline would affect M. tuberculosis by 
blocking its peptidoglycan biosynthesis by targeting murE', which 
needs to be validated experimentally.  
 
 
Figure 2: Molecular interactions of murE and three of the prioritized drugs. Figure A displays the target protein in solid ribbon form, 
gray in colour with interacting amino acids highlighted in line form, blue in colour while the docked lymecycline is displayed in stick 
form, green in colour. The intermolecular hydrogen bonds are displayed in dotted lines, red in colour. The magnified view of the 
interactions for better clarity is provided in the Figure B; semi-transparent surface over lymecycline (yellow in colour) and interacting 
amino acids labelled with three letter code. The effective fitting of the acarbose and desmopressin in the active site groove of the murE 
is clearly displayed in figure C & D respectively; acarbose and desmopressin is highlighted in semi-transparent surface (yellow in 
colour) and displayed in stick form. 
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Out of the 17 drugs prioritized by multiple rounds of docking, in 
addition to lymecycline, six more drugs, namely fidaxomicin, 
indinavir, caspofungin, vancomycin, micafungin and polymyxin 
B sulfate are also known to be used against bacterial, viral or 
fungal infections (Table 1) [14]. The mechanism of these drugs, in 
general, they inhibit essential proteins of the respective 
pathogens, thus, blocking their life cycle in one way or the other. 
For example, lymecycline binds to bacterial 30S ribosomal 
subunit and prevent translation of proteins [14]. Vancomycin 
prevents gram-positive bacterial cell-wall biosynthesis by 
inhibiting the incorporation of N-acetylmuramic acid and N-
acetylglucosamine peptide subunits into the peptidoglycan 
matrix [14]. Indinavir is known to inhibit protease of HIV that is 
required for proteolytic cleavage of the viral polyprotein 
precursors into the individual functional proteins [14]. Strong 
binding of these seven drugs (which are primarily used against 
other pathogens) with murE of M. tuberculosis indicates that they 
could be potential candidate drugs for repurposing or serve as 
leads for new drug discovery for tuberculosis. 
 
The prioritized drugs in the present study have come through 
several rounds of filtering, thus, they are worthy for further 
investigation by experimental studies.  The aim and scope of our 
present study is to prioritize drugs by in silico virtual screening 
and suggest them for further studies for repurposing. However, 
we performed literature search to know whether any of the 
prioritized drugs are already validated in vitro against 
tuberculosis. Interestingly, it was observed that totally 4 drugs, 
namely acarbose, fidaxomicin (Synonyms: lipiarmycin), 
vancomycin and polymyxin B sulfate have been reported to have 
anti-mycobacterial activity by other researchers. Caner et al., 
(2013) demonstrated acarbose to strongly bind to trehalose 
synthase (treS) which is involved in essential functions such as 
energy storage, signaling, protein-protection and bacterial cell 
wall components of M. tuberculosis [18]; thus, Caner et al (2013) 
reported that acarbose could be used as a competitive inhibitor of 
treS of M. tuberculosis [18]. Fidaxomicin is also known as 
lipiarmycin, was demonstrated to have inhibitory activity against 
multidrug-resistant strains of M. tuberculosis [19]. Recently, 
vancomycin and tetrahydrolipstatin were reported to show 
synergistic inhibitory activity on M. bovis BCG and on M. 
tuberculosis [20]. Polymyxin B (synonymous: polymyxin B sulfate) 
was reported to show bactericidal activity against M. smegmatis 
[21]. Indinavir was shortlisted as a potential drug for repurposing 
for TB by another bioinformatics based study [22]. Since four of 
the 17 drugs are already reported to have anti-mycobacterial 
activity in vitro, we are encouraged to suggest these 17 prioritized 
drugs as potential candidates for further exploration towards 
repurposing for TB. Additionally, the same fact that four of the 
prioritized drugs have in vitro anti-mycobacterial activity 
strongly supports our procedure as a valid one and convinces us 
that it can be used as a generic protocol for prioritization of drugs 
for repurposing for other clinical conditions. Our protocol has 
identified 12 existing drugs as potential candidates for 
repurposing towards TB for the first time based on virtual 
screening against murE of M. tuberculosis. We started the present 
study with 1554 FDA approved drugs and subjected them 
through a series of stringent filtering criteria of multi-level 
docking which resulted in 17 prioritized drugs as potential 
candidates for repurposing for the treatment of TB.  
 
Conclusion: 
Our study has several intrinsic advantages. Since our starting 
materials for virtual screening were already FDA approved drugs 
for other clinical use (but not for TB) and human safety issues are 
well established, if these drugs are proved to show efficacy for TB 
in vivo in animal models in future, they can be expedited for 
clinical research directly in TB patients. Further, drugs have been 
screened against one of the essential proteins, murE, which is 
involved in the making of cell wall of the M. tuberculosis; thus, 
drug-inhibitors identified for this enzyme would potentially have 
fatal consequence on the bacteria. The bioinformatics protocol we 
applied in this study has helped us to prioritize 17 drugs 
including those which were already reported to have in vitro 
activity against M. tuberculosis; this observation serves as a 
validation and proof-of-concept for our protocol that we have 
conceptualised and applied in this study. Encouraged by these 
results, we have undertaken some of the prioritized drugs for 
further experimental studies towards repurposing for 
tuberculosis. 
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